MD & VP South Asia: Annaswamy Vaidheesh
Revenue: Rs 400 crore
GSK India's vaccines business revenue for FY2015-16 stood at over Rs 400 crore compared to Rs 440 crore in FY2014-15.
In FY2015-16, GlaxoSmithKline India's biggest milestone was its investment in building its new tablet manufacturing factory in Vemgal, Karnataka, with a whopping investment of Rs 1,000 crore.
The facility is expected to be fully operational in 2017. The factory is said to manufacture more than 8 billion tablets and 1 billion capsules in areas of gastroenterology and anti-inflammatory medicines for the Indian market.
In June last year, the company announced the appointment of Annaswamy Vaidheesh, as GSK India's VP for South Asia and MD, succeeding Dr Hasit Joshipura.
In September 2015, GSK Pharmaceuticals completed acquiring Novartis' vaccines business. In April 2016, the company launched its school sanitation project at Nashik, Maharashtra.